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Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy:
analysis by myositis autoantibody and pathological features
Aim: Juvenile idiopathic inflammatory myopathies have
been recently reclassified into clinico-serological sub-
groups. Myopathological correlates of the subgroups
are incompletely understood. Methods: We studied
muscle biopsies from 101 children with clinically and
serologically defined juvenile idiopathic inflammatory
myopathies from the UK JDM Cohort and Biomarker
Study by applying the international JDM score tool,
myopathological review and C5b-9 complement analy-
sis. Results: Autoantibody data were available for 90/
101 cases with 18/90 cases positive for anti-TIF1c,
15/90 anti-NXP2, 11/90 anti-MDA5, 5/90 anti-Mi2
and 6/90 anti-PmScl. JDM biopsy severity scores
were consistently low in the anti-MDA5 group, high
in the anti-Mi2 group, and widely distributed in the
other groups. Biopsies were classified histologically as
perifascicular atrophy (22/101), macrophage-rich
necrosis (6/101), scattered necrosis (2/101), clustered
necrosis (2/101), inflammatory fibre invasion (2/
101), chronic myopathic change (1/101), diffuse
endomysial macrophage infiltrates (40/101) and min-
imal change (24/101). MDA5 cases segregated with
the minimal change group and showed no capillary
C5b-9-deposition. The Mi2 group displayed high
severity scores and a tendency towards sarcolemmal
complement deposition. NXP2 and TIF1c groups
showed a variety of pathologies with a high propor-
tion of diffuse endomysial macrophage infiltrates and
a high proportion of capillary C5b-9 deposition. Con-
clusion: We have shown that juvenile idiopathic
inflammatory myopathies have a spectrum of
histopathological phenotypes and show distinct
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complement attack complex deposition patterns. Both
correlate in some cases with the serological subtypes.
Most cases do not show typical histological features
associated with dermatomyositis (e.g. perifascicular
atrophy). In contrast, more than half show relatively
mild histopathological changes.
Keywords: anti-SRP, dermatomyositis, immune mediated necrotizing myopathy, JDM score tool, polymyositis,
principal component analysis
Introduction
Juvenile idiopathic inflammatory myopathies (IIM) are a
group of diseases comprising immunologically mediated
inflammatory muscle diseases in children. This group of
diseases is being re-appraised and reclassified based on
an improved understanding of the autoantibody land-
scape and clinical phenotypes. In the traditional clinico-
pathological classification, juvenile IIMs include juvenile
dermatomyositis, polymyositis and cases that ‘overlap’
with other connective tissue diseases. A parallel serologi-
cal classification based on myositis-specific antibodies
(MSA) and myositis-associated antibodies (MAA) has
emerged over the past decade. Initial correlation between
the clinical findings and autoantibody groups revealed
subphenotypes allowing a refined clinical description of
these diseases [1]. There are few studies analysing the
correlation between the serological subtypes and muscle
biopsy findings in adults and very few for juvenile IIM.
Early classification of IIMs on histopathological grounds
into dermatomyositis, polymyositis, and inclusion body
myositis was based on histochemical and morphological
criteria. In 2003, an enlarged morphological ENMC classi-
fication also comprising nonspecific myositis and immune
mediated necrotizing myopathies was published based on
an international workshop consensus [2]. The serological
data in adult IIM patients suggested morphological and
immunohistochemical subtypes for antisynthetase autoan-
tibody associated myositis [3–5], MDA5-associated der-
matomyositis [6], and a correlation between HGMCR and
SRP serological groups and immune mediated necrotizing
myopathy [7]. Differences in C5b-9 deposition pattern
have been suggested for anti-Mi2 and anti-TIF1c serologi-
cal groups [8,9]. Integration of these and other findings
into a clinico-sero-pathological classification for adult IIMs
is ongoing [9–11]. In contrast, juvenile IIMs are rare and
few sero-pathological correlations have been reported. Our
group has previously shown differences in histopathologi-
cal severity between the MDA5 and Mi2 serological groups
[12,13] and described distinctive features of the paediatric
patients positive for MDA5 [13]. SRP and HMGCR serolog-
ical groups appear to be associated with necrotizing myo-
pathies in children as they are in adults [14–16]. Detailed
histological studies in large serologically well-defined
cohorts have not been published to date, partly due to the
rarity of such cohorts. The UK Juvenile Dermatomyositis
cohort and biomarker study (JDCBS) and repository pro-
vides a unique opportunity in this regard.
Several rare and less well-correlated myopathological
manifestations of inflammatory muscle disease have
been described in addition to the more frequent pat-
terns, including inflammatory myopathy with abun-
dant macrophages (IMAM) [17] and regional infarct-
like change [18]. Furthermore, in clinical practice,
muscle biopsies often have variable or nonspecific find-
ings in children clinically suspected to have an
immune-mediated condition. These observations show
a potential spectrum of histopathological findings seen
in individual patients diagnosed with IIMs.
Our study describes systematically the biopsy pathol-
ogy of a large cohort of clinically and serologically
diagnosed juvenile IIM patients, and to test the hypoth-
esis that specific features may be associated with
autoantibody groups. This cohort allows an unbiased
view of the pathological changes in these diseases,
since patient selection was not based on histological
criteria. We adopted a two-stage approach. In the first
stage, we analysed the biopsies in a standardized man-
ner using our validated international JDM biopsy score
tool [19,20], and in a second stage we conducted an
independent and blinded descriptive histopathological
review of dominant pathological features.
Methods
Patients, biopsy material and clinical data
Paediatric patients with clinically diagnosed idiopathic
inflammatory myopathy with or without skin changes
were recruited to the UK JDCBS [21]. Diagnosis was
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based on probable or definite Bohan and Peter Criteria.
Written informed parental consent and age appropriate
assent were obtained from participants prior to inclusion
in the study. This research was approved by the North-
ern & Yorkshire Multi-centre Research Ethics Commit-
tee, UK. Muscle biopsies from quadriceps were available
for 101 patients in the JDCBS. Treatment status at time
of biopsy, CK levels, clinical diagnosis and assessment
were recorded. As a global measure of muscle strength,
the Childhood Myositis Assessment Scale (CMAS; range
0–52 with high scores indicating normal strength) was
applied in the majority of cases at the time of diagnosis.
Stains and immunohistochemistry
Frozen sections were stained with Haematoxylin &
Eosin, modified G€om€ori trichrome (GT), NADH tetra-
zolium reductase and Acid Phosphatase. Immunohisto-
chemical studies were performed as described
previously [12,19,20]. The following primary antibod-
ies were used: anti-human CD3 (UCHT1), anti-human
CD68 (KP1), anti-human major histocompatibility com-
plex class I heavy chain (W6/32) and anti-human
neonatal myosin (WB-MHCn) from Novacastra, UK;
anti-human CD31 (JC70A) from Dako, Cambridgeshire,
UK, and anti-human C5b-9 (Ae11) from Dako.
Severity scoring of biopsies
Scoring of biopsy samples was conducted using the val-
idated JDM biopsy score tool as described previously
[19,20]. Briefly, severity of pathology was assessed in
four domains: inflammatory, vascular, muscle fibre and
connective tissue. The number of inflammatory cells
infiltrating endomysial, perimysial and perivascular
regions on CD3 and CD68 staining, was assessed and
scored according to cell density and presence of clus-
ters, as specified previously. Components of the muscle
fibre domain used to determine abnormalities were
over-expression of MHC class I, expression of neonatal
myosin, assessment of the number of atrophic, necrotic,
degenerating and regenerating fibres within fascicles
and in peri-fascicular regions and presence of internal
nuclei. Vascular pathology was assessed by determining
loss of CD31 capillary staining, vessel abnormalities
and infiltration and the presence or absence of infarc-
tion. Excess collagen and fibrosis was assessed on GT
stains in endomysial and perimysial regions. The total
score was calculated as the sum of the domain scores.
Total biopsy scores across these domains can range
from 0 to 27, with higher scores indicating more sev-
ere pathology. All biopsy severity scores were assessed
by a single observer (SAY), who was blinded to the
autoantibody status of each patient.
Histological review of biopsies
In parallel with the use of the score tool, histological
review of all 101 biopsies was carried out by a senior
neuropathologist (PWS) independently of, and blinded
to, scoring results, autoantibody status and clinical data.
Stains and immunohistochemical studies were available
as stated above. The aim of the histological review was a
descriptive assessment of the dominant pathological fea-
tures in each muscle biopsy. Groups were largely based
on findings described in the context of typical myopatho-
logical diagnoses, such as perifascicular atrophy (PFA)
in classic dermatomyositis, macrophage rich necrosis in
IMAM [17], inflammatory fibre invasion (FI) in inclusion
body myositis, scattered necrosis (SN) in immune medi-
ated necrotizing myopathies, and clustered necrosis (CN)
in regional ischemic immune myopathy [18]. It is impor-
tant to emphasize that we wish to distinguish between
descriptive histological groups used for this study and
the diagnostic entities related to them.
Autoantibody screening
Serum or plasma were screened for autoantibodies using
immunoprecipitation as described previously [12]. The
following controls were used as standard: Normal serum,
anti-Jo1, -PL7, -PL12, -Zo, -U1, -RNAPII, -PmScl, -Ro60,
-La, -Mi2, -Ku, -SAE, -RNAPI/III, -U3, -TIF1c, -SRP, -
Scl70 and 140 kDa band. ELISA was used to confirm
specificity for anti-NXP2 or anti-MDA5 in patients with
a 140 kDa band. All specimens were additionally
screened by ELISA for anti-HMGCR antibody. If no
autoantibody bands at all were detected, the case was
put in the ‘NIL’ group. It is important, however, to note
that the absence of detectable bands on immunoprecipi-
tation does not exclude the presence of autoantibodies.
For some analyses, autoantibody bands of unknown
specificity were present. The group of ‘no identifiable
autoantibodies’ (NIA) comprised those cases with no
bands and those with an unidentifiable band. For initial
evaluations of score tool data, the NIL group was used as
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comparison group. For analysis of the histopathological
categories, the NIA group was felt to be more compre-
hensive and better suited.
Statistical analysis
Principal component analysis (PCA) was performed on
the entire cohort to reduce the number of dimensions
in the severity score data and enable visualization of
potential underlying clusters. PCA analysis was per-
formed using the R package FactoMineR [22]. Vascular
domain features were excluded because they displayed
the least variance. Steroid treatment was included as
parameter to control for its effects. Visualization of the
PCA analysis used the coordinates for each patient on
the first two principal components, coloured according
to the autoantibody group.
The distributions of domain score totals, CMAS score
and dominant fibre pathology categories across autoan-
tibody groups were analysed by Kruskal–Wallis test
(GraphPad Prism 5 GraphPad Software, La Jolla, Cali-
fornia, USA). For categorical variables, groups with
small sample size (n < 2) were excluded from statistical
analysis. Post-hoc comparisons were performed using
Dunn’s Multiple Comparison Test. Differences in
autoantibody frequency across histological groups were
analysed by the chi square test. For all analyses, P-
values of <0.05 were considered statistically significant.
PCA of score tool data and subsequent analysis of
domain specific data is based on all 101 cases, includ-
ing cases treated with steroids at the time of biopsy,
since steroid treated did not show a significant effect on
total severity scores, as shown by Mann–Whitney test
on total severity scores, P = 0.52. All cases were indi-
vidually reviewed and assigned to histological groups.
Analysis of the correlation of histological groups with
serological and clinical data was restricted to cases
without treatment at the time of biopsy.
Results
One hundred and one biopsies from patients with juve-
nile idiopathic inflammatory myopathy were included
in this study. Table 1 shows the demographic and clini-
cal features of the group including autoantibody
results. Antibodies against Jo1, PL12, Zo, Ro60, La,
Ku, RNAPII, RNAPI/II, U3, Scl70 and HMGCR were
not detected in this cohort.
Pathological severity scores were distributed widely
from mild to severe across the entire cohort
All 101 muscle biopsies in the cohort were assessed
using the validated JDM muscle biopsy score tool
[19,20]. This tool measures the severity of pathology in
muscle biopsies in four domains (inflammatory, muscle
fibre, vascular, connective tissue). Total scores across
the entire cohort had a wide distribution with a range
from 2 (almost normal) to 26 (severe); an interquartile
range of 10–21; and a median of 17. We hypothesized
that this variability is related to the differing underlying
autoantibody groups in the cohort. To test the possibil-
ity that variability was related to serological type, we
analysed the data according to autoantibody sub-
groups.
Autoantibody stratification showed differences in
total severity scores between MDA5 and Mi2 groups
As we have previously shown, muscle biopsy scores for
patients with MDA5-associated myopathies cluster in
the mild range, Mi2-associated cases cluster in the severe
range, and TIF1c- and NXP2-associated cases vary
across a wide range, Figure 1 [12]. To further analyse
these findings, we conducted PCA using all 101 sets of
biopsy score data. The first principal component, which
captured 40.8% of the total variance in the pathological
scores, separated the anti-MDA5 and anti-Mi2 cases into
separate clusters (Figure 1a). No other myositis specific
autoantibody subgroups separated into clusters when
projected onto the first two principal components, indi-
cating that the score tool data could not explain the
underlying variability in these groups. To better under-
stand the source of this variability of the total scores, we
next investigated the domain specific score data.
Differences in total scores were accounted for by
variability in the myofibre and inflammatory
subdomains
In the PCA, inflammatory and muscle fibre domain
scores accounted for a large proportion of the variance
between these two groups. Domain specific analysis of
the score tool data confirmed that the severity of
inflammatory infiltrates and of fibre pathology differ
between Mi2 and MDA5 antibody subgroups, whereas
other myositis specific autoantibody groups, in
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particular TIF1c and NXP2, had a wide range of scores
for severity in these domains. (Figure 1b,c). No signifi-
cant differences between groups were seen in the vas-
cular and connective tissue domains (data not shown).
Severity scores correlated weakly with muscle strength
at time of biopsy as we have shown previously [19],
and MSA status also showed associations with muscle
strength at the time of biopsy (Figure 1d).
Preliminary histological examination showed that all
patients with autoantibodies to Mi-2 had significant
pathological change in their biopsies (Figure 1e). In par-
ticular, there were high levels of inflammation and a
range of fibre pathology including PFA, necrosis and sev-
ere chronic myopathic changes. In contrast, the majority
of patients with autoantibodies to MDA5 had very mild,
almost normal, muscle biopsies, with little or no inflam-
mation and minimal myofibre abnormalities, such as
increased fibre size variability (Figure 1e). However, eight
of nine cases showed increased MHC Class I expression.
Representative biopsy pathology for a patient with
Mi2 and MDA5 autoantibodies are shown in Figure 1e,
with intense inflammatory infiltrates and muscle fibre
damage in the Mi2 group and minimal changes (MC)
in the MDA5 group.
The MDA5 group contained one outlier case both on
PCA and domain-specific analysis that did not cluster
with other cases in the MDA5 group. This case scored
higher for muscle fibre pathology, which showed PFA
and SN (Figure 1b). This patient also had a long time
interval between disease onset and muscle biopsy of
approximately 5 years, which could be related to the
increased severity of pathology seen in this biopsy.
Overall, score tool data analysis demonstrated that
severity of muscle pathology is not randomly dis-
tributed across autoantibody groups in juvenile IIM.
The score tool gives an overall measure of severity
but does not indicate the underlying type of pathology.
We hypothesized that there may be variation in the
patterns of pathology that might explain the variability
in the biopsies. Therefore, in our second analysis,
biopsy histology was reviewed by an experienced
pathologist who was blinded to score tool data, as well
as the clinical and serological features. The primary
aim was to determine if a pattern of pathology could
be recognized in each biopsy and if so whether these
findings correlated with serological or clinical data.
JIIM patients show a variety of myopathological
changes that could be summarized in distinct
histopathological groups
Descriptive categories and their frequency in this
cohort are summarized in Table 2. There were several
biopsies in our cohort with only mild abnormalities












Age at onset (years) 6.1 [3.9–9.3]
Time from disease onset to
diagnosis, (months)
2.6 [1.5–7.5]
Time from diagnosis to
biopsy, (months)
0.72 [0.39–0.92]
On steroids at biopsy, n (%) 12 (12.2)
CMAS at biopsy 29 [18.75–45]
Reported clinical diagnosis, n (%)












Focal myositis 1 (1)




Antibody Status, n 90 of 101












No identifiable autoantibodies, n (%) 28 of 90 (31.1)
Autoantibody status data were available in 90 cases. Percentages
reflect the number of patients with a given antibody as a propor-
tion of total tested patients.
CMAS, Childhood Myositis Assessment Scale.
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and no significant inflammatory infiltrates. We called
this group of cases ‘MC’ (24/101 cases; 19/89
untreated cases; Figure 2a–e). Next, we identified a
group that was distinguished by diffusely increased
endomysial CD68-positive cells in combination with
increased sarcolemmal MHC class I expression, which
we called the ‘diffuse endomysial macrophage infiltra-
tion’ pattern (DEMI; 40/101 cases; 36/89 untreated
cases; Figure 2f–j). This group was formally defined by
the presence of an endomysial macrophage infiltrate
score of 2, combined with MHC class I overexpression,
but no or only rare atrophic or necrotic muscle fibres.
Biopsies with DEMI infiltrates occasionally displayed
rare regenerating fibres or rare lymphocytic infiltrates,
but by definition, these were not prominent features.
Another large group was characterized by PFA (22/
101 cases; 19/89 untreated cases; Figure 2k–o). PFA
affected more than one layer of atrophic fibres on the
edge of at least one fascicle. Small numbers of necrotic
fibres were sometimes observed, but these were not a
dominant feature. Biopsies with PFA often had
increased perimysial lymphocytic infiltrates, and endo-
mysial and perimysial fibrosis. A small group of biopsies
was characterized by extensive and diffuse fibre necro-
sis, numerous macrophages and moderate, often endo-
mysial, lymphocytic infiltrates, which we designated as
the ‘macrophage-rich necrosis’ pattern (MRN; 6/101
cases; 6/89 untreated; Figure 2p–t). Necrotic fibres in
various stages of myophagocytosis were found in both
peri- and intrafascicular location, scattered or
confluent. PFA was sometimes present as a minor
component.
Rare cases showed other distinctive pathologies. Two
cases demonstrated clusters of necrotic fibres resem-
bling a small infarct, termed ‘CN’, but no significant
inflammatory infiltrates (2/101 cases; 2/89 untreated
cases; Figure 3a–e). Two cases had scattered necrotic
fibres (2/101 cases; 2/89 untreated cases; Figure 3f–j)
with very little inflammation, as is typically described
in immune-mediated necrotizing myopathy. Two cases
showed invasion of normal appearing muscle fibres by
lymphocytes, grouped as inflammatory FI (2/101 cases;
2/89 untreated cases; Figure 3k–o). A single biopsy
exclusively showed features of a severe chronic myopa-
thy (Figure 3p–t) with marked fibre size variation,
internal nucleation and frequent whorled fibres.
Finally, two biopsies could not be assigned to any of
the above groups and were classified in an ‘other’ cate-
gory. One of these showed features of neurogenic
change and the other of diffuse fibre necrosis at a simi-
lar stage of phagocytosis consistent with
Table 2. Frequency of histological groups in the biopsy cohort,
n = 101
Dominant histological pattern n (%)
Minimal change 24 (24)
Diffuse endomysial macrophage infiltrates 40 (40)
Perifascicular atrophy 22 (22)
Macrophage rich necrosis 6 (6)
Clustered necrosis 2 (2)
Scattered necrosis 2 (2)
Fibre invasion 2 (2)
Chronic myopathic 1 (1)
Other 2 (2)
Figure 1. MDA5 and Mi-2 autoantibody groups define clusters of mild and severe pathology (a) Principal component analysis of each
feature of the biopsy tool for each biopsy sample. Each symbol indicates an individual case, plotted on the two principal components that
capture the most variance in the data, with the percentage of variance captured given in parentheses. Triangles are coloured according
to auto-antibody groups as indicated. (b,c) Domain totals for each of the domains in the juvenile dermatomyositis biopsy score tool
according to autoantibody subgroups. The inflammatory domain represents the sum of scores for CD3 and CD68 positive endomysial,
perimysial and perivascular cells, the muscle fibre domain represents the sum of scores for MHC class I expression, neonatal myosin
expression, perifascicular and non-perifascicular atrophy and fibre degeneration and regeneration, and internal nucleation. Kruskal–
Wallis ANOVA was performed to compare the distribution of domain totals across myositis-specific antibodies/myositis-associated antibodies
subgroups. Post-hoc analysis indicated that the inflammatory domain scores differed between the anti-Mi2 and anti-MDA5, anti-MDA5
and anti-TIF1c, and anti-MDA5 and anti-NXP2 cases. The muscle fibre domain scores differed between the anti-Mi2 and anti-MDA5
cases. Nil: no autoantibody bands detected on immunoprecipitation analyis. (d) Correlation of autoantibody group and muscle weakness,
as assessed by the Childhood Myositis Assessment Scale (CMAS). Kruskal–Wallis ANOVA was used to compare the degree of muscle
weakness across autoantibody subgroups. Post-hoc comparisons indicated that CMAS differed between the anti-Mi2 and anti-MDA5 cases,
with Mi2 cases being much weaker. (e) Representative micrograph images of representative Mi2 (a–g) and MDA5 (h–n) muscle biopsies.
Mi2 cases typically had high levels of inflammation, fibre damage and vessel abnormalities, while MDA5 cases had a much more normal
appearance with only mild fibre size variation. a,b,h,i – Haematoxylin & Eosin (H&E), c,j – CD3, d,k – CD68, e,l – CD31, f,m – neonatal
myosin, g,n – MHC class1. Scale bars for micrographs a and h are shown in h, length 250 lm, scale bars for b–g and i–n shown in i,
length 100 lm.
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Figure 2. Illustrations of the histological features of the frequent histological groups in the biopsy cohort. The example of minimal
change (a–f) demonstrates increased fibre size variability in the absence of macrophage infiltrates on CD68 immunohistochemistry. The
example of diffuse endomysial macrophage infiltrates (g–l) also shows mild fibre pathology, but has increased endomysial CD68 labelling
combined with overexpressed MHC class I. The illustration of perifascicular atrophy (m–r) shows several layers of atrophic cells in
perifascicular distribution with marked peri- and endomysial lymphocytic infiltrates (CD3). Note that endomysial CD68 labelling is also
increased and that necrosis is largely absent. The example of macrophage rich necrosis (s–x) shows numerous, often intrafascicular,
necrotic fibres in various stages of myophagocytosis, a dense macrophage infiltrate (CD68) and a less dense lymphocytic infiltrate (CD3).
Images chosen show typical changes although do not capture the full histological variability in each group. Scalebars: for micrographs a,
g,m,s, bar shown in s, length 250 lm; for remaining micrographs bar shown in t, length 100 lm.
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rhabdomyolysis (the clinical impression in this case
was described as ‘focal myositis’).
Rare biopsies showed combinations of main
pathological features
The majority of biopsies displayed features which fell
into one of the categories defined above. In just four
cases were two distinct patterns seen in different areas
of the biopsy. Two cases had PFA and macrophage rich
necrosis. One of these was from a patient with anti-Mi2
antibody, the other from the patient with anti-MDA5
antibody who had a long disease course before biopsy,
as mentioned above. These cases were excluded from
the further correlational analysis. Another two cases
showed marked chronic myopathic change in addition
to PFA. These cases were classified as PFA with the
chronic myopathic change assumed to be secondary.
Biopsies with DEMI infiltrates have a serological
profile which is distinct from MC biopsies
To test the significance of the histopathological differ-
ences between MC and DEMI (DEMI) cases, we com-
pared the autoantibody profile of both groups
restricting biopsies to patients without steroid treatment
at the time of biopsy. Analysis of the major myositis-
specific autoantibody groups demonstrated a clearly
distinct distribution (Figure 4a): MC cases account for
almost all of the MDA5 group whereas DEMI cases
were mostly NXP2 or TIF1c, or NIA cases. None of the
MC or DEMI cases had Mi2 antibodies. These results
suggest that the distinction between MC and DEMI
may be biologically significant. Differences between
these two groups were apparent upon analysis of asso-
ciated inflammatory infiltrates with generally higher
lymphocyte scores in DEMI compared to MC (Fig-
ure 4b,c). Histological groups correlated well with dis-
tinct ranges of JDM severity scores (Figure 4d).
NXP2, TIF1c and Mi2 groups were
myopathologically heterogeneous compared to the
MDA5 group, which was characterized by MC
The myositis-specific autoantibody groups NXP2, TIF1c
and Mi2 showed more than one pathological pattern
on biopsy (Figure 4e). In the NXP2 and TIF1c serologi-
cal groups, a combination of biopsies with DEMI
infiltrates and PFA was present, explaining partly the
variability of the severity scores observed in the first
stage of this study. Interestingly, there were also other
pathological patterns present, illustrated by a case with
CN and one case with macrophage rich necrosis in the
NXP2 (Figure 4e). The Mi-2 group appeared more
homogeneous on score tool analysis with generally
high severity scores, but upon histological review also
showed heterogeneous histological patterns with two
cases of PFA, one case of macrophage rich necrosis
and one case with chronic myopathic change (Fig-
ure 4e). All biopsies from untreated patients in the
MDA5 group showed MC pathology with notable
absence of inflammatory infiltrates and very little fibre
pathology, with one exception noted above.
Complement attack complex deposition patterns
vary between serological subgroups
C5b-9 immunohistochemical studies were available for
96/101 biopsies and for 76/89 biopsies from
untreated patients. Figure 5 shows the results of com-
plement labelling in a capillary or sarcolemmal pat-
tern or no labelling, defined as neither capillary, nor
sarcolemmal, across serological and histological groups
for untreated cases. Capillary deposition pattern con-
sisted of at least 2–3 clustered and dot-like comple-
ment deposits in capillaries, whereas sarcolemmal
deposition consisted of granular circumferential deco-
ration of muscle fibre membranes. The negative
groups showed neither pattern but may show comple-
ment deposition in necrotic fibres. The vast majority
of cases with capillary C5b-9 labelling were found in
the TIF1c and NXP2 groups, or the group with no
identifiable antibodies. The Mi2 cases showed a
increased proportion of sarcolemmal labelling com-
pared to capillary labelling and the MDA5 group did
not show cases with capillary labelling. For statistical
analysis, we merged the groups with sarcolemmal
complement deposition and with no complement depo-
sition into a single category of no capillary comple-
ment deposition to ensure meaningful group sizes. Chi
square analysis of the larger MSA groups (MDA5,
Mi2, NXP2, TIF1c) with variables grouped into capil-
lary complement deposition and no capillary comple-
ment shows statistically differences between groups
(P = 0.002). However, Fisher’s exact test did not
demonstrate differences between the NXP2 and Mi2
© 2019 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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Figure 3. Illustrations of histological features of rare histological groups in the biopsy cohort. The example of clustered necrosis (a–f)
illustrates an area of necrotic fibres surrounded by relatively normal appearing muscle in the absence of significant lymphocyte (CD3) or
macrophage (CD68) infiltrates. Only occasional macrophages are present in necrotic fibres. Scattered necrosis (g–l) is reminiscent of the
findings in immune-mediated necrotizing myopathy. The example shows two scattered necrotic fibres undergoing myophagocytosis with
macrophage infiltrates (CD68) and remarkably little inflammation (CD3). Two cases demonstrated inflammatory invasion of normal
appearing muscle fibres in combination with endomysial lymphocytic infiltrates (m–r). These biopsies typically also had a significant
number of necrotic fibres. A single biopsy showed only marked chronic myopathic change (s–x) with marked fibre size variability and
hypertrophy, internal nucleation, whorled fibres and endomysial fibrosis. Images chosen show typical features, although they do not
capture the full histological variability in each group. Scalebars: for micrographs a,g,m,s, bar shown in s, length 250 lm; for remaining
micrographs, bar shown in t, length 100 lm.
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Figure 4. Serological profiles of the histological groups and correlation of the histological groups with the JDM severity score tool results.
Patients were included in the analysis if they were untreated at the time of biopsy and if serological data were available (83/101). (a)
Analysis of serological profiles of the histological groups. The MC group has a significantly different serological profile from the DEMI
group (P = 0.002) and the PFA group (P = 0.041; Chi-square test), while no statistically significant difference was apparent between
DEMI and PFA (P = 0.3) or between PFA and MRN (P = 0.08); chi-square test for all comparisons; *P < 0.05. (b) Total severity score
from the international score tool as correlated with dominant fibre pathology. (c,d) Correlation of more frequent pathological patterns
with lymphocytic and macrophage infiltrates. Total CD3 and CD68 scores are the sums of endomysial, perimysial and perivascular scores
from the international score tool. (e) Plot of severity scores across autoantibody groups subclassified according to dominant fibre
pathology. MC, minimal change; DEMI, diffuse endomysial macrophage infiltrates; PFA, perifascicular atrophy; MRN, macrophage rich
necrosis; CN, clustered necrosis; SN, scattered necrosis; FI, fibre invasion; CM, chronic myopathic change.
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groups. Given the small numbers, however, a differ-
ence cannot be excluded. Labelling patterns analysed
according to histological subgroup are in keeping with
the serological profile of each group, considering that
the main serological groups in DEMI and PFA are
NXP2, TIF1c and NIA (Figure 4a). A summary of the
correlation of serological groups with histological
groups, complement deposition pattern and JDM sever-
ity scores in absolute numbers is presented in Table 3.
Biopsy pathology in the PmScl and SRP
autoantibody groups is in keeping with reports from
adult patients
Several observations are warranted for the smaller
autoantibody groups and for MAA. PmScl patients did
not show PFA on biopsy, but a mixture of MRN, inflam-
matory FI and endomysial macrophage infiltrates. Con-
versely, all cases with inflammatory FI fell into the
PmScl group in keeping with a traditionally assumed
association of PmScl with polymyositis [23]. There were
two SRP cases in this cohort and both presented with a
histological pattern of immune mediated necrotizing
myopathy, in keeping with observations from adult
cohorts. These cases have been independently reported
[14].
Clinical diagnosis and CMAS score do not correlate
with descriptive histological groups
Juvenile dermatomyositis (probable or definite by
Bohan and Peter criteria; [24,25]) was by far the most
frequent clinical diagnosis in our cohort (88%)
(Table 1). Clinical diagnoses are listed with correspond-
ing histological patterns in Table 4. Given the small
numbers of patients with clinical diagnoses other than
juvenile dermatomyositis, it is not possible to draw defi-
nite conclusions from these data. No statistically signifi-
cant correlation of histological patterns and CMAS
scores, which were available for 88/101 patients,
emerged (Figure 6a). Although the MC group shows an
aggregate of high CMAS scores, and this is consistent
with previous observations in MDA5 +ve JDM, there
were also several patients with a low CMAS score in
this group, possibly related to the serological hetero-
geneity of this group as presented in Figure 4.
CK levels show differences across histological
patterns
CK levels were available for 73/101 cases (Figure 6b).
Only cases without prior steroid treatment were taken
into consideration. Upon Kruskal–Wallis testing, there
were significant differences between the major histolog-
ical groups (Figure 6b). The MC histological group
showed low CK levels (highest 550 IU/l; Figure 6b;
P = 0.03 vs. DEMI and MRN and P = 0.04 vs. PFA,
Mann–Whitney test) with exception of a single case
































































Figure 5. Correlation of complement attack complex (C5b-9)
deposition pattern with serological and histological groups across
the study cohort. The results of immunohistochemical staining for
C5b-9 were available for 76 patients after restriction to patients
not on steroid treatment at the time of biopsy. Patient numbers
whose biopsies showed capillary complement deposition,
sarcolemmal complement deposition, or neither are plotted
against (a) serological and (b) histological groups. For statistical
analysis cases with sarcolemmal membrane attack complex
deposition and without any deposition were merged into a single
category in order to ensure meaningful group sizes. For results
see text. MC, minimal change; DEMI, diffuse endomysial
macrophage infiltrates; PFA, perifascicular atrophy; MRN,
macrophage rich necrosis; CN, clustered necrosis; SN, scattered
necrosis; FI, fibre invasion; CM, chronic myopathic change. NIA,
no identifiable autoantibodies.
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TIF1c serological group and showed capillary comple-
ment deposition, in contrast with the MDA5 cases in
the MC group. The wide range of CK levels in the histo-
logical group with DEMI infiltrates is remarkable and
may suggest that these pathological features on biopsy
can indeed be associated with considerable muscle
abnormality and, as indicated by the CMAS score, with
muscle weakness. There was no statistically significant
difference between the PFA and DEMI group (P = 0.79,
Mann–Whitney test).
Discussion
This study examines muscle biopsies from a cohort of
101 patients with juvenile immune mediated
myopathies to probe potential associations of
myopathological features with autoantibody groups.
Inclusion in the cohort was based on a clinical diagno-
sis of juvenile IIM. 90/101 cases underwent serological
analysis by immunoprecipitation for myositis-specific
and myositis associated autoantibodies. Seventy percent
of cases tested had identifiable autoantibodies. Since
biopsy pathology was thus studied in an unbiased
cohort with selection criteria which were independent
of biopsy results, this study provided an opportunity for
a comprehensive analysis of muscle biopsy pathology
in this disease group.
Mi2 patients demonstrated consistently high JDM
severity scores, displayed a variety of histological pat-
terns including PFA, macrophage rich necrosis and
Table 3. Correlation of serological groups with JDM severity score, histological groups and complement deposition pattern
Severity score MC DEMI PFA MRN CN SN CM IF Other Total C5b-9 cap C5b-9 sarc C5b-9 neg
MDA5 9 (7–9.5) 8 0 1 0 0 0 0 0 0 9 0/9 1/9 8/9
Mi2 21 (19–24) 0 0 2 2 0 0 1 0 0 5 1/5 2/5 3/5
TIF1c 16 (12–20) 3 9 3 0 0 0 0 0 0 15 9/13 1/13 3/13
NXP2 19 (12–22.5) 1 7 4 1 1 0 0 0 0 14 9/13 1/13 3/13
SRP 13.5 (12–15) 0 0 0 0 0 2 0 0 0 2 0/2 0/2 2/2
PL7 19 0 1 0 0 0 0 0 0 0 1 1/1 0/1 1/0
SAE 14 0 1 0 0 0 0 0 0 0 1 1/1 0/1 1/0
PmScl 24 (12–25) 0 2 0 2 0 0 0 2 0 6 0/5 2/5 3/5
U1RNP 20 (18–22) 0 1 0 0 0 0 0 0 1 2 1/2 0/2 1/2
Scl70 10 1 0 0 0 0 0 0 0 0 1 1/1 0/1 1/0
NIA 17 (12–21) 4 13 8 1 1 0 0 0 0 27 15/24 3/24 6/24
Total 17 34 18 6 2 2 1 2 1 83
Severity score is displayed as median (interquartile range). Other columns show patient numbers. Included are all patients who had sero-
logical analysis and who were without steroid treatment at the time of biopsy (83/101). C5b-9 studies were not available for all patients
and total numbers are indicated as fractions of total studies available in respective columns.
NIA, no identifiable autoantibody; MC, minimal change; DEMI, diffuse endomysial macrophage infiltrates; PFA, perifascicular atrophy;
MRN, macrophage rich necrosis; CN, clustered necrosis; SN, scattered necrosis; IFI, inflammatory fibre invasion; CM, chronic myopathic;
C5b-9 cap, C5b-9 deposition in a capillary pattern; C5b-9 sarc, C5b-9 deposition in a sarcolemmal pattern; C5b-9 neg, neither sarcolem-
mal nor capillary complement deposition.
Table 4. Clinical diagnosis and histological groups in 89/101 patients without steroid treatment at the time of diagnosis
MC DEMI PFA MRN CN SN IFI CM Other
JDM 18/89 33/89 17/89 4/89 2/89 1/89 0 1/89 1/89
JDM with scleroderma 1/89 0 1/89 2/89 0 0 2/89 0 0
JDM with chronic polyarthritis 0 1/89 1/89 0 0 0 0 0 0
PM 0 0 1/89 0 0 1/89 0 0 0
Focal myositis 0 0 0 0 0 0 0 0 1/89
Other 0 1/89 0 0 0 0 0 0 0
JDM, juvenile dermatomyositis; PM, Polymyositis; ‘Other’, Inflammatory myopathy clinically not otherwise specified; MC, minimal change;
DEMI, diffuse endomysial macrophage infiltrates; PFA, perifascicular atrophy; MRN, macrophage rich necrosis; CN, clustered necrosis; SN,
scattered necrosis; IFI, inflammatory fibre invasion; CM, chronic myopathic.
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chronic myopathic change, and a tendency towards
sarcolemmal rather than capillary complement deposi-
tion. The NXP2, TIF1c and no identifiable autoanti-
body groups were characterized by a considerable
variability in severity scores, a significant proportion of
biopsies with DEMI infiltrates and MHC upregulation,
several biopsies with PFA, and overall a large propor-
tion of cases with capillary complement deposition. No
myopathological differences between these three latter
groups were apparent on the present analysis. The
increased propensity for sarcolemmal complement
deposition in the Mi2-associated myopathies compared
to NXP2 or TIF1c has been previously reported in adult
patients and our data suggest a similar relationship in
juvenile IIMs [9]. The absence of differences between
the NXP2 and TIF1c on the present morphological
analysis and C5b-9 immunohistochemical profile does
not exclude more subtle differences that might exist for
instance on a protein expression level or in regard to
subgroups of inflammatory cells. Further studies may
clarify such potential differences.
Capillary deposition of C5b-9 was present in a vari-
able proportion in several autoantibody groups in our
paediatric cohort. Results from adult TIF1c-positive
patients indicate that in this age group, C5b-9 deposi-
tion is significantly associated with paraneoplastic
myositis [8]. Paraneoplastic myositis is rare in children
and has not been seen to date in this cohort of 101
cases. The question of whether capillary complement
deposition is a biomarker of other disease characteris-
tics in juvenile inflammatory myopathies calls for fur-
ther study and will be the focus of long-term outcome
and follow up studies in this cohort.
MDA5-associated myopathies generally had mild
pathology according to the JDM score-tool, did not
show DEMI infiltrates or other inflammatory infiltrates,
and lacked capillary C5b-9 deposition. These cases clus-
ter in the histological ‘MC’ group. The absence of major
morphological changes in biopsies from juvenile MDA5
patients is in keeping with previous reports of minimal
fibre pathology in both juvenile and adult cohorts of
anti-MDA5 associated dermatomyositis [6,13], suggest-
ing that paediatric MDA5 cases demonstrate similar
myopathology to adult cases. It remains to be seen
whether changes in nitric oxide synthase expression, as
shown in biopsies from adult patients, could be repli-
cated in a paediatric cohort.
Our data suggest a pathomechanistic role for diffuse
macrophage infiltrates, which are characteristic of the
DEMI group. DEMI histology was found in a large pro-
portion of patients from several serological groups and
clinically often typical dermatomyositis. It has a sero-
logical profile distinct from the MC group, a different
distribution of CK values, and different complement
deposition patterns. Endomysial macrophages secrete
the highly pro-inflammatory protein MRP8/14 in juve-
nile dermatomyositis [26], supporting a significant















































Figure 6. Correlation of (a) CMAS score and (b) CK levels with
histological groups. CMAS scores were available for 88 untreated
patients while CK levels were available for 73 untreated patients.
Groups with small sample size (n < 2) were excluded from the
statistical analysis. Bars indicate median; multiple comparisons by
Kruskal–Wallis test, individual comparisons by Mann–Whitney
test. CMAS, Childhood Myositis Assessment Scale; MC, minimal
change; DEMI, diffuse endomysial macrophage infiltrates; PFA,
perifascicular atrophy; MRN, macrophage rich necrosis; CN,
clustered necrosis; SN, scattered necrosis; IFI, inflammatory fibre
invasion; CM, chronic myopathic change.
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studies on the subtypes and pathogenetic contribution
made by these tissue macrophages are warranted.
The rare myopathological manifestations of MSA-
associated inflammatory myopathies are an interesting
group in our cohort. Previous publications on these are
available mostly as small series of adult patients with
pathologies such as macrophage rich inflammation and
clusters of necrotic fibres [17,18]. Similar patterns are
present in this paediatric cohort, in small numbers in
several serological groups. CN was previously reported
as a characteristic of regional ischemic immune myopa-
thy and was suspected to be associated with NXP2
autoantibodies in the original series [18]. Our data sug-
gest a similar association in juvenile IIMs. Their poten-
tial clinical significance in paediatric patients is largely
unknown and deserves further study.
MAA-associated biopsies show a spectrum of patholo-
gies often similar to those that have been reported in
adult cases. Invasion of healthy appearing fibres by
inflammatory cells is a feature associated with tradi-
tional myopathological descriptions of polymyositis and
has been reported in association with PmScl antibodies
in adult patients [23]. Scattered necrosis is typically
seen in immune mediated necrotizing myopathies [10].
In our cohort, this occurred exclusively in the SRP
group suggesting that immune mediated necrotizing
myopathy associated with SRP has similar muscle
pathology in adults and children. We have previously
reported these cases [14].
The international JDM score tool has been systemati-
cally standardized and its application across this large
cohort produced robust evidence of a correlation
between low scores in the MDA5 and high scores in the
Mi2 serological groups, while the NXP2 and TIF1c posi-
tive groups of patients showed a wide range of scores.
Scoring also produced an array of data from different
histopathological domains, which is amenable to
advanced cluster analysis. This type of analysis appears
well-suited to muscle biopsies given that histopathologi-
cal assessments normally integrates numerous morpho-
logical findings. PCA revealed clusters defined by
inflammatory and fibre pathology parameters, indicating
a high discriminatory value of these domains. Interest-
ingly, assessment of these domains shows the highest
interobserver agreement on validation studies [15]. The
present study combines quantitative evaluation and
histopathological classification to create a robust over-
view of myopathological changes in a large cohort.
The descriptive histological categories used in this
study correlate poorly to not at all with clinical diagno-
sis and CMAS score. There are likely multiple factors
causing this variability. The pathophysiology of muscle
weakness in inflammatory myopathies is poorly under-
stood and by implication their correlation with mor-
phological change is not obvious. CK levels correlate
somewhat better with histological groups than CMAS
values probably for similar reasons given that the for-
mer reflects muscle fibre degeneration and loss of mem-
brane integrity.
A challenge for any study of pathological subgroups
of IIM is to analyse the great variety of myopathologi-
cal findings that can be seen in order to allow correla-
tion with clinical or serological classifications. The JDM
score tool delivers a standardized assignment of a sever-
ity score but was not designed to convey all aspects of
individual myopathological change. To complement the
score tool data, we reviewed all biopsies and chose to
group them in descriptive categories based on the dom-
inant pathological features seen in each biopsy. The
histological categories used are modelled on major
pathologies previously described in the myopathological
literature on inflammatory myopathies. In some cases,
precise definitions are difficult since the visual interpre-
tation of ‘significant atrophy’, for instance, may vary
from one pathologist to another. Yet, these categories
are meant to uncover basic patterns and not to serve
as discriminators for diagnostic entities. The fact that
no apparent differences were disclosed between the
NXP2, TIF1c group and the group without identifiable
autoantibodies does not exclude possible differences
between these groups in regard to other markers of
pathology. Importantly, this study did not aim to define
diagnostic criteria using histological features. The
strength of our study resides in an unbiased overview
of a large cohort with a diverse autoantibody spectrum.
In conclusion, we have mapped myopathological
manifestations in a large cohort of patients with clini-
cally and serologically defined juvenile IIM using a dual
approach with evaluation based on the validated JDM
score tool in a first stage and histological review and
grouping in a second. Our results show certain biopsy
characteristics of the MDA5 and Mi2 serological
groups, but no obvious differences between NXP2,
TIF1c and the group with NIA. Endomysial macro-
phage infiltrates were a prominent feature in many
biopsies with the notable exception of the MDA5 group,
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supporting a pathomechanistic role for tissue macro-
phages. Biopsies from myositis-specific autoantibody
groups demonstrated histological variability and vari-
able proportions of capillary C5b-9 deposition. The clin-
ical and pathomechanistic significance of this
variability deserves further study.
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